PROTEÍNA MONOSPECÍFICA COM REGULAÇÃO DO PONTO DE VERIFICAÇÃO IMUNE PD-L1 PARA TERAPIA DO CÂNCER
Bispecific antibodies targeting OX40 and PD-L1 are developed to overcome the limitations of current immune checkpoint blockers, enhancing T cell activation and antitumor immunity, offering improved therapeutic efficacy in various cancers.
Patent Information
- Application Number
- BR122026025174
- Authority / Receiving Office
- BR · BR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-12-29
- Filing Date
- 2018-12-28
- Publication Date
- 2026-11-10
AI Technical Summary
Current cancer treatments using immune checkpoint blockers like anti-PD-1 and anti-CTLA-4 antibodies are not sufficiently active for many patients, and additional immunomodulatory pathways in the tumor microenvironment need to be targeted to enhance antitumor immunity.
Development of bispecific antibodies that bind to OX40 and PD-L1, combining the activation signals for T cells to enhance antitumor immunity, with the antibodies being engineered to have a human Fc domain for stability and targeting multiple epitopes simultaneously.
The bispecific antibodies stimulate T cell proliferation and cytokine production, enhancing antitumor immune responses and potentially leading to durable clinical responses in cancers such as prostate, lung, melanoma, lymphoma, breast, head and neck, RCC, and ovarian cancer.
Description
1 / 46 “PD-L1 IMMUNE CHECKPOINT REGULATED MONOSESPECIFIC PROTEIN FOR CANCER THERAPY” BACKGROUND Field of Invention Split order of order BR112020013133-4 from 12 / 28 / 2018.
[0001] The present invention relates to an antibody. More particularly, the present invention relates to an antibody for cancer therapy. Description of the Related Technique
[0002] The two main types of lymphocytes in humans are T (thymus-derived) and B (bone marrow-derived). These cells are derived from hematopoietic stem cells in the bone marrow and fetal liver that have committed to the lymphoid developmental pathway. The progeny of these stem cells follow divergent paths to mature into B or T lymphocytes. The development of human B lymphocytes occurs entirely in the bone marrow. T cells, on the other hand, develop from immature precursors that leave the marrow and travel through the bloodstream to the thymus, where they proliferate and differentiate into mature T lymphocytes. T cells
[0003] T cells are the most abundant cells (approximately 75% of blood lymphocytes) and potent immune killers. The role of effector T cells in the antitumor immune response is strongly supported by in vitro studies and the observation that a high infiltration of CD8+ T cells in various tumor types correlates with a favorable clinical prognosis (Fridman et al., 2012). Activation of unchallenged T cells Petition 870260102302, dated 05 / 10 / 2026, p. 10 / 103 2 / 46 effector receptors require at least three complementary signals: (i) TCR-CD3 / Ag-MHC interaction with assistance from coreceptors (CD4 or CD8); (ii) binding of costimulatory molecules such as CD80 or CD86 to CD28, CD40 / CD40L; and (iii) accessory molecules such as cytokines.
[0004] Co-stimulation, or the delivery of two distinct signals to T cells, is a widely accepted model of activation of resting T lymphocytes by antigen-presenting cells (APCs) (Lafferty and Cunningham, 1975). This model also provides a distinction between self-tolerance and immunological tolerance (Bretscher and Cohn, 1970; Bretscher, 1999; Jenkins and Schwartz, 1987). The primary signal, or antigen-specific signal, is transduced through the T cell receptor (TCR) after recognition of the foreign antigenic peptide presented in the context of the naive histocompatibility complex (MHC). The second signal, or co-stimulatory signal, is delivered to T cells by co-stimulatory molecules expressed on antigen-presenting cells (APCs) and induces T cells to promote clonal expansion, cytokine secretion, and effector function (Lenschow et al., 1996).In the absence of co-stimulation, T cells may become refractory to antigen stimulation, fail to mount an effective immune response, and, moreover, result in exhaustion or tolerance to foreign antigens. Immune checkpoint protein: PD-L1 and OX40
[0005] Immune checkpoints refer to a group of inhibitory and stimulatory pathways, initiated primarily by ligand-receptor interaction, Petition 870260102302, dated 05 / 10 / 2026, page 11 / 103 3 / 46 which links the immune system, specifically T cell-mediated immunity, to maintain self-tolerance and modulate the duration and amplitude of physiological responses in peripheral tissues to normally minimize collateral tissue damage (Pardoll, 2012). Tumor cells co-opt certain checkpoint pathways as an important immune resistance mechanism. For example, programmed cell death protein ligand 1, PD-L1, is generally upregulated on the surface of human cancer tumor cells. The interaction of PD-L1 with its receptor, PD-1, expressed on tumor-infiltrating lymphocytes (TILs), specifically T cells, inhibits the local T cell-mediated response to escape immune surveillance (Liang et al., 2006; Sznol and Chen, 2013). Thus, inhibition of immunosuppressive signals in cancer cells, or direct agonistic stimulation of T cells, results in and / or induces a strong, sustained antitumor immune response.Recent clinical studies have strongly suggested that blocking immune checkpoint proteins via antibody or modulated by soluble ligands or receptors are the most promising approaches to activate therapeutic antitumor immunity (Topalian et al., 2014). Currently, anti-PD-1 and anti-CTLA-4 (cytotoxic T lymphocyte-associated antigen-4) antibodies have been approved by the FDA to treat diseases such as melanomas.
[0006] Another co-stimulatory molecule is the OX40 receptor (CD134), a membrane-bound element of the TNFR superfamily, expressed primarily on activated CD4+ T cells (Paterson et al., 1987). A Petition 870260102302, dated 05 / 10 / 2026, page 12 / 103 4 / 46 Signaling via the OX40 receptor (hereinafter O40) is co-stimulatory for effector T cells and causes T cell proliferation (Watts, 2005; Weinberg et al., 1994). Studies of OX40 suggest that its main role is to dictate the number of effector T cells that accumulate in primary immune responses and, consequently, govern the number of memory T cells that subsequently develop and survive (Croft, 2003). Several in vitro studies have demonstrated that OX40 provides a co-stimulatory signal, resulting in increased T cell proliferation and cytokine production. Bispecific / bifunctional antibody
[0007] The idea of using bispecific antibodies to efficiently redirect effector immune cells to tumor cells emerged in the 1980s (Karpovsky et al., 1984; Perez et al., 1985; Staerz et al., 1985). Bispecific scaffolds are generally classified into two main groups with different pharmacokinetic properties, based on the absence or presence of an Fc fragment: IgG-like molecules and small recombinant bispecific scaffolds, most of which are derived from the single-chain variable fragment (scFv). Due to their compact size, antibody fragments generally penetrate tumors more efficiently than IgG-like molecules, but this benefit is mitigated by a short serum half-life (a few hours), limiting their total tumor uptake and residence time (Goldenberg et al., 2007). On the other hand, the presence of an Fc fragment, which binds to neonatal Fc receptors, provides a serum half-life. Petition 870260102302, dated 05 / 10 / 2026, p. 13 / 103 5 / 46 long (> 10 days) to IgG-type formats, favoring tumor uptake and retention, but limiting tumor penetration.
[0008] Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of cancer treatments that utilizes the patient's immune system to destroy cancerous cells. Within a tumor, the presence of a family of negative regulatory molecules, collectively known as checkpoint inhibitors, can inhibit T cell function to suppress antitumor immunity. Checkpoint inhibitors, such as CTLA-4 and PD-1, attenuate T cell proliferation and cytokine production. Targeted blockade of CTLA-4 or PD-1 with antagonistic monoclonal antibodies (mAbs) releases the brakes on T cells to enhance antitumor immunity. Generating optimal CD8 killer T cell responses also requires T cell receptor activation plus co-stimulation, which can be provided through binding of elements of the tumor necrosis factor receptor family, including OX40 (CD134) and 4-1 BB (CD137).OX40 is of particular interest as treatment with an activating anti-OX40 mAb (agonist) increases T cell differentiation and cytolytic function, leading to enhanced antitumor immunity against a variety of tumors. When used as single agents, these drugs can induce potent clinical and immunological responses in patients with metastatic disease (Linch et al., 2015). SUMMARY Petition 870260102302, dated 05 / 10 / 2026, page 14 / 103 6 / 46
[0009] The present disclosure designed to investigate a bispecific antibody with immunomodulatory intent for the treatment of cancer patients, such as prostate cancer, lung cancer, NSCLC, melanoma, lymphoma, breast cancer, head and neck cancer, RCC or ovarian cancer was examined.
[0010] The present disclosure provides an Antibody or its antigen-binding portion that binds to OX40 (CD134), comprising: a variable heavy chain region comprising an amino acid sequence of at least about 80% sequence homology with respect to the amino acid sequence selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, amino acids 128-246 of SEQ ID NO. 10 and amino acids 124-241 of SEQ ID NO. 13; and a variable light chain region comprising an amino acid sequence of at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-108 of SEQ ID NO. 5, 1-108 of SEQ ID NO. 7, 1-112 of SEQ ID NO. 10 and 1-108 of SEQ ID NO. 13.
[0011] In one embodiment, the antibody or its antigen-binding moiety is a single-strand variable fragment (scFv) sequence selected from the group consisting of SEQ ID Nos. 10, 11, 12 and 13.
[0012] In one embodiment, the antibody or its antigen-binding moiety is a bispecific antibody.
[0013] In one embodiment, the bispecific antibody comprises a binding site for the immune checkpoint protein.
[0014] In one embodiment, the linking site to Petition 870260102302, dated 05 / 10 / 2026, p. 15 / 103 7 / 46 The immune checkpoint protein comprises a programmed cell death protein 1 ligand binding site (PD-L1), a PD-1 binding site, an epidermal growth factor receptor (EGFR) binding site, a human epidermal growth factor receptor 2 (HER2) binding site, a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) binding site, or a lymphocyte activation gene 3 (LAG3) binding site.
[0015] The present disclosure also provides an antibody or antigen-binding moiety that binds to PD-L1, comprising: a variable heavy chain domain comprising an amino acid sequence of at least about 80% sequence homology with respect to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4; and a variable light chain domain comprising an amino acid sequence of at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-111 of SEQ ID NO. 1 and 1-110 of SEQ ID NO. 3).
[0016] The present disclosure also provides a bispecific antibody comprising at least one polypeptide chain, wherein the polypeptide chain comprises an OX40 binding site and a PD-L1 binding site. The OX40 binding site comprises a variable region of the heavy chain comprising an amino acid sequence of at least about 80% sequence homology with respect to the selected amino acid sequence from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, amino acids 128-246 of SEQ ID NO. 10 and amino acids 124-241 Petition 870260102302, dated 05 / 10 / 2026, p. 16 / 103 8 / 46 SEQ ID NO. 13; and a variable light chain region comprising an amino acid sequence of at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-108 of SEQ ID NO. 5, 1-108 of SEQ ID NO. 7, 1-112 of SEQ ID NO. 10, and 1-108 of SEQ ID NO. 13). The PD-L1 binding site comprises a variable heavy chain domain comprising an amino acid sequence of at least about 80% sequence homology with respect to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4; and a variable light chain domain comprising an amino acid sequence of at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-111 of SEQ ID NO. 1 and 1-110 of SEQ ID NO. 3).
[0017] In one embodiment, the polypeptide chain further comprises an Fc domain, a Fab fragment, and an scFv. The Fab fragment is connected to the N-terminus of the Fc domain and comprises the PD-L1 binding site. The scFv is connected to the C-terminus of the Fc domain and comprises the OX40 binding site.
[0018] In one embodiment, the polypeptide chain further comprises a linker between the Fc domain and the scFv.
[0019] In one embodiment, scFv comprises an amino acid sequence selected from the group consisting of amino acids 455-707 of SEQ ID NO. 18, 455-708 of SEQ ID NO. 19, 455-701 of SEQ ID NO. 20, 455-706 of SEQ ID NO. 21, 455-706 of SEQ ID NO. 22, 455-706 of SEQ ID NO. 23, Petition 870260102302, dated 05 / 10 / 2026, page 17 / 103 9 / 46 455-706 of SEQ ID NO. 24, 455-706 of SEQ ID NO. 25, 455-706 of SEQ ID NO. 26, 455-706 of SEQ ID NO. 27, 455-706 of SEQ ID NO. 28 and 455-706 of SEQ ID NO. 29
[0020] In one embodiment, the bispecific antibody comprises a pair of polypeptide chains.
[0021] In one embodiment, the bispecific antibody is an IgG, IgE, IgM, IgD, IgA, or IgY antibody.
[0022] In one embodiment, the bispecific antibody is an IgG antibody.
[0023] In one embodiment, the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.
[0024] The present disclosure also provides an antibody-drug conjugate comprising a therapeutic agent and an antibody or antigen-binding moiety that binds to PD-L1 and / or OX40, wherein the therapeutic agent is covalently conjugated to the antibody or antigen-binding moiety by a ligand.
[0025] In one embodiment, the antibody or an antigen-binding moiety is selected from the aforementioned antibody or antigen-binding moiety.
[0026] The present disclosure also provides a pharmaceutical composition comprising the antibody, the antigen-binding moiety or the bispecific antibody as mentioned above and at least one pharmaceutically acceptable carrier.
[0027] The present disclosure also provides a method of treating cancer, comprising administering to the individual in need an effective amount of the antibody, its antigen-binding moiety, or the antibody. Petition 870260102302, dated 05 / 10 / 2026, page 18 / 103 10 / 46 bispecific, as mentioned above.
[0028] In one embodiment, the cancer is selected from the group consisting of prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), and ovarian cancer.
[0029] The present disclosure also provides a nucleic acid molecule that encodes the antibody, its antigen-binding portion, or the bispecific antibody as mentioned above.
[0030] It should be understood that both the general description above and the detailed description below are merely illustrative and are intended to provide a further explanation of the invention as claimed. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The invention can be more fully understood by reading the following detailed description of the embodiment, with reference to the accompanying drawings as follows:
[0032] Figure 1 shows immune checkpoints modulating T cell-mediated immunity. Agonistic or antagonistic antibodies against checkpoints, such as anti-ICOS, anti-CD28, anti-OX40 and anti-CD27, or anti-PD-1, anti-CTLA4, anti-LAG3, anti-BTLA, could be used to construct the bifunctional fusion protein, depending on the applications.
[0033] Figures 2A and 2B show the classification of the phage clone by direct ELISA for HEK293 cells expressing PD-L1. Petition 870260102302, dated 05 / 10 / 2026, page 19 / 103 11 / 46
[0034] Figures 3A and 3B show the classification of the phage clone by ELISA based on HEK293 cells expressing OX40.
[0035] Figure 4 shows purified antibody derivatives specific for PD-L1 by SDS-PAGE with non-reducing reagent to reveal integrity and purity.
[0036] Figure 5 shows purified antibody derivatives specific for OX40 by SDS-PAGE with non-reducing or reducing reagent to reveal integrity and purity.
[0037] Figure 6 shows examples of the direct ligand binding activity of purified anti-immune checkpoint proteins and anti-PD-L1 antibody derivatives against PD-L1. The ligand-precoated wells were first incubated with various concentrations of antibody derivatives, as indicated. The bound proteins were then detected with HRP-conjugated goat anti-human IgG Fab specific antibody and the OD450 readings were plotted.
[0038] Figure 7 shows examples of the direct ligand binding activity of purified anti-immune checkpoint proteins and anti-OX40 antibody derivatives against OX40. The ligand-precoated wells were first incubated with various concentrations of antibody derivatives, as indicated. The bound proteins were then detected with HRP-conjugated goat anti-human IgG Fab specific antibody and the OD450 readings were plotted. Petition 870260102302, dated 05 / 10 / 2026, page 20 / 103 12 / 46
[0039] Figure 8 shows the flow analysis using PD-L1 expressing 293 cells. PD-L1 expressing HEK293 cells were first incubated with purified antibody derivatives and bound antibodies were detected with Alexa-488-conjugated goat anti-human IgG (H+L), followed by analysis by fluorescence-activated cell sorter (FACS).
[0040] Figure 9 shows flow analysis using OX40-expressing 293 cells. OX40-expressing HEK293 cells were first incubated with purified anti-OX40 antibody derivatives and bound antibodies were detected with Alexa-488-conjugated goat anti-human IgG (H+L), followed by FACS analysis. NS: no staining.
[0041] Figure 10 shows the blocking of the PD-1 / PD-L1 interaction with purified anti-PD-L1 antibodies. The purified antibodies as indicated were applied with biotinylated PD-L1-Fc and recombinant human PD-1 / His (hPD-1 / His) to evaluate the inhibition activity of the PD-1 / PD-L1 interaction. The binding of PD-L1-Fc and recombinant hPD-1 / His was detected by streptavidin-HRP and ELISA analysis.
[0042] Figures 11A and 11B show anti-PD-L1 antibody derivatives with 1 or 10 μg / mL, stimulating T cell proliferation and inducing IL-2 and / or IFN-γ production in a mixed lymphocyte reaction (MLR) assay after antibody treatment for 3 days (Figure 11A) or 5 days (Figure 11B).
[0043] Figure 12A shows the ability of anti-OX40 antibody derivatives to enhance activation. Petition 870260102302, dated 05 / 10 / 2026, page 21 / 103 13 / 46 of the CD3+ T cells respond to the assay and also to the reference antibody. Figure 12B shows the concentration of human IL-2 and IFN-γ present in the cell culture media after 3 days of stimulation of human T cells with plate-bound anti-CD3 and various concentrations of anti-OX40 antibody derivatives.
[0044] Figures 13A and 13B show the concentration of human IL-2 (Figure 13A) and IFN-γ (Figure 13B) present in the cell culture medium after 3 days of stimulation of human T cells with plate-bound anti-CD3 and various concentrations of OX40-specific antibody derivatives.
[0045] Figure 14 shows the structure of an Fc antibody heavy chain fused with an OX40-specific scFv domain.
[0046] Figure 15 shows examples of PAGE-gel analysis of anti-immune checkpoint antibodies to human OX40 fusion proteins. It has been shown that purified fusion proteins, anti-PD-L1-OX40 scFv fusion proteins, have a molecular weight of approximately 220 kDa (non-reducing), and the heavy chain fusion has approximately 85 kDa and the light chain is approximately 25 kDa (reduced) in both antibody fusions.
[0047] Figures 16A and 16B show bispecific synergistic antibodies that stimulate T cell activation for IL-2 and IFN-γ production in a mixed lymphocyte response (MLR) assay after 3 days (Figure 16A) or 5 days (Figure 16B) with mono-, combined, or anti-PD-L1-OX40 scFv bispecific antibody treatment. Petition 870260102302, dated 05 / 10 / 2026, page 22 / 103 14 / 46
[0048] Figures 17A to 17E show, respectively, the determination of aggregation and purity of Bispecific antibodies, Anti-PD-L1-OX40 Ab and Anti-PD-L1OX40 Ab-V1 to V4, with 5 different ligands in OX40 scFv.
[0049] Figure 18 shows sequence variants between the OX40 B17 scFv clone of Anti-PD-L1-OX40 Ab-V4 to V12 (SEQ ID NOS: 30-38).
[0050] Figure 19 shows examples of PAGE-gel analyses of anti-immune checkpoint antibodies to human OX40 fusion proteins. It has been shown that purified fusion proteins, anti-PD-L1-OX40 Ab-V5 fusion proteins, have a molecular weight of approximately 220 kDa (unreduced), and the heavy chain fusion has approximately 80 kDa and the light chain is approximately 30 kDa (reduced) in both antibody fusions.
[0051] Figure 20 shows a flowchart illustrating the ELISA method for evaluating the binding activity of bispecific antibody variants.
[0052] Figure 21 shows the binding activity to human PD-L1 of the bispecific antibody variants and their EC50.
[0053] Figure 22 shows the human OX40 binding activity of the bispecific antibody variants and their EC50.
[0054] Figure 23 shows the ex vivo serum stability of the antiPD-L1-OX40 Ab-V5 bispecific antibody variant.
[0055] Figures 24A and 24B show IL-2 production for 3 days (Figure 24A) and IFN-γ production for 5 days (Figure 24B) after T cell modulation with Petition 870260102302, dated 05 / 10 / 2026, page 23 / 103 15 / 46 bispecific antibody treatment mono-, combined or antiPD-L1-OX40 Ab-V5.
[0056] Figure 25 is a graph showing the effect of treatment with bispecific anti-PD-L1-OX40 Ab-V5 antibodies and treatment with monoclonal antibodies on PC-3 tumor growth in Fox Chase SCID® Beige mice. DETAILED DESCRIPTION
[0057] Detailed reference will now be made to the present embodiments of the invention, examples of which are illustrated in the accompanying drawings. Whenever possible, the same reference numbers are used in the drawings and description to refer to the same or similar parts.
[0058] The present invention describes the expression, purification, and characterization of bifunctional proteins with isolated functional OX40 scFv agonist fused to the C-terminus of the Fc domain of anti-immune checkpoint protein antibodies. These proteins, interacting with their corresponding target checkpoint, are intended to transmit the inhibitory or stimulatory signal to modulate T cell-mediated immunity. The Fc fusion protein components in the present invention are all of human origin and are therefore expected to be non-immunogenic and usable as therapeutics in humans.
[0059] Bispecific molecules, such as bispecific antibodies (BsAbs), provide a means of simultaneously targeting multiple epitopes on the same molecular target or different targets with a single agent. Petition 870260102302, dated 05 / 10 / 2026, p. 24 / 103 16 / 46 therapeutic. As cancer therapeutics, they have the potential to confer new or more potent activities, reduce the cost of products, and facilitate the development of new therapeutic regimens, in contrast to a mixture of two mAbs (Chames and Baty, 2009; Hollander, 2009; Thakur and Lum, 2010). Recently, catumaxomab, a bispecific trifunctional antibody targeting human epithelial cell adhesion molecule (EpCAM) and CD3, has shown a clear clinical benefit in patients with peritoneal carcinomatosis of epithelial cancers (Heiss et al., 2010), and a bispecific T-cell targeting antibody (BiTE) with dual specificity for CD19 and CD3 has also demonstrated encouraging clinical activity in CD19-expressing hematologic malignancies (Bargou et al., 2008).Despite strong interest in the development of bispecific molecules as cancer therapeutics, technical challenges in producing stable and active bispecific molecules in the past have hindered the clinical evaluation of most bispecific formats. Many engineered antibody formats, including one IgG-like bispecific antibody, have compromised stability or solubility (Bargou et al., 2008; Demarest and Glaser, 2008; Lu et al., 2005). Furthermore, several strategies have been adopted to increase product quality and in vivo stability of bispecific molecules, including PEGylation, conjugation with human serum albumin, and Fc engineering (Muller et al., 2007; Ridgway et al., 1996). Single-chain bispecific antibodies of the general form described above have the advantage that the nucleotide sequence encoding the four V domains... Petition 870260102302, dated 05 / 10 / 2026, page 25 / 103 17 / 46 Two linkers and a spacer can be incorporated into a suitable host expression organism under the control of a single promoter. This increases the flexibility with which these constructs can be designed, as well as the degree of experimenter control during their production. Furthermore, the Fc of IgG is another attractive support for the design of novel therapeutics, as it contains all the functions of antibodies except the binding capacity. Fc engineering is important for improving the efficacy of bispecific antibodies. Therefore, the IgG-based conformation is being used in the present invention for two independent targets in immune cells or target cells in immunotherapy.
[0060] Immune checkpoint target proteins are promising approaches to activate antitumor immunity. Checkpoint proteins, such as PD-1, PD-L1, CTLA-4, LAG3, etc., are currently being clinically evaluated (Figure 1). Preliminary data with immune checkpoint protein blockers have demonstrated the ability to enhance antitumor immunity with the potential to produce durable clinical responses. However, despite the remarkable clinical efficacy of these agents in various neoplasms, it has become clear that they are not sufficiently active for many patients. Several additional immunomodulatory pathways, as well as inhibitory factors expressed or secreted by myeloid and stromal cells in the tumor microenvironment, are potential targets to synergize with immune checkpoint blockade. Therefore, the combination of anticancer therapies or bispecific antibodies has been essential to achieve complete remission and cures for Petition 870260102302, dated 05 / 10 / 2026, page 26 / 103 18 / 46 patients with cancer.
[0061] The present invention describes the construction, expression, and characterization of an anti-mune checkpoint protein Fc antibody fused with different checkpoint protein-specific scFv proteins. The OX40 scFv positioned at the C-terminus in fusion constructs should allow expansion of the power of the fusion proteins beyond the OX40 activation approach if the fusion counterpart is an immune system-enhancing agent, such as an anti-EGFR, anti-HER2, or anti-CTLA-4 antibody, for example. Generation of antibodies from the OmniMab library.
[0062] For the generation of therapeutic antibodies against PD-L1 or OX40, selections were made in the OmniMab phage library. The phage library is generated by AP Biosciences Inc. (APBio Inc.) from a collection of over one hundred B cells from healthy donors. Phages for the first round of selection were prepared by Hyperphage (M13K07ΔρIIII, Progen, Heidelberg, Germany). Solid-phase cycle and cell cycle against PD-L1 or OX40 were applied for selection of specific PD-L1 or OX40 ligands and isolation from the OmniMab library. The solid-phase cycle was performed using recombinant human PD-L1-Fc or OX40-Fc (APBio Inc.) in the first round of selection, and then HEK293 cells expressing PD-L1 or OX40 were used for two or three rounds of enrichment. After three rounds of selection, specific PD-L1 or OX40 ligands were sorted and isolated by ELISA or by direct cell-based ELISA with the corresponding recombinant protein. Petition 870260102302, dated 05 / 10 / 2026, p. 27 / 103 19 / 46 (Figures 2A, 2B, 3A, and 3B). Pre-coated recombinant PDL1-Fc or OX40 proteins expressed in 293 cells were stained with a supernatant containing rescued phages for 1 hour and washed three times with PBS containing 0.1% Tween-20. Bound phages were detected by HRP-conjugated anti-M13 antibody (Roche), and TMB substrate was used for signal development. OD450 readings were recorded. Positive ligands were isolated and sent for sequencing to confirm sequencing and diversity of the heavy and light chains. The variable region of the heavy and light chains specific to PD-L1 or OX40 was described from SEQ ID NO. 1 to SEQ ID NO. 8: SEQ ID NO. 1 is the light chain of clone PD-L1 6, SEQ ID NO. 2 is the variable region of the heavy chain of clone PD-L1 6, SEQ ID NO. 3 is the light chain of clone PD-L1 32, SEQ ID NO. 4 is the variable region of the heavy chain of clone PD-L1 32, SEQ ID NO.5 is the light chain of clone OX40 B17, SEQ ID NO. 6 is the variable region of the heavy chain of clone OX40 B17, SEQ ID NO. 7 is the light chain of clone OX40 B19, SEQ ID NO. 8 is the variable region of the heavy chain of clone OX40 B19. As shown in figures 2A, 2B, 3A and 3B, several clones have been isolated and known to be specifically recognized for the corresponding antigen as compared to the negative control. Subcloning and expression / purification of a specific ligand selected for PD-L1 or OX40 as an IgG format.
[0063] To facilitate the rapid classification of specific ligands with functionality in the activation of Petition 870260102302, dated 05 / 10 / 2026, page 28 / 103 20 / 46 T cells, the heavy and light chains of ligands positive against PD-L1 or OX40 by ELISA were then amplified, digested, and subcloned into the APBio-specialized IgG expression vector, carrying the constant region of IgG4 (SEQ ID NO. 9). After sequence validation, the plasmids were then prepared and transfected into HEK293 cells for antibody expression with fetin 293 transfection reagent (Invitrogen). After 4 days of culture, the antibody segregated into serum-free medium is purified by affinity chromatography of the culture supernatant using protein G chromatography. The purified antibody is then concentrated, followed by dialysis in PBS buffer. The final concentration of the dialyzed protein is determined by NanoDrop2000 spectrophotometer, and purity and integrity are determined by SDS-PAGE with or without reducing reagent, as shown in Figures 4 and 5.The integrity of various purified antibody derivatives, specific for PD-L1 or specific for OX40, is normal in HEK293 cells, as is the reference antibody, MPDL3280A for PD-L1 or GSK3174998 for OX40.
[0064] In one embodiment, the present disclosure provides an antibody or antigen-binding portion that binds to OX40 (CD134), comprising a variable heavy chain region and a variable light chain region. The variable heavy chain region comprises an amino acid sequence exhibiting at least about 80% sequence homology with respect to the amino acid sequence selected from the group consisting of SEQ ID NO. 6, SEQ ID NO. 8, amino acids 128-246 of SEQ ID NO. 10, and amino acids 124-241 of SEQ ID NO. 13. In some Petition 870260102302, dated 05 / 10 / 2026, page 29 / 103 In 21 / 46 examples, the variable region of the heavy chain comprises an amino acid sequence exhibiting at least about 85%, 90%, or 95% sequence homology with respect to the amino acid sequence as mentioned above. The variable region of the light chain comprises an amino acid sequence exhibiting at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-108 of SEQ ID NO. 5, 1108 of SEQ ID NO. 7, 1-112 of SEQ ID NO. 10, and 1-108 of SEQ ID NO. 13. In some examples, the variable region of the light chain comprises an amino acid sequence with at least about 85%, 90%, or 95% sequence homology with respect to the amino acid sequence as mentioned above.
[0065] In one embodiment, the present disclosure provides an antibody or antigen-binding portion that binds to PD-L1, comprising a variable heavy chain domain and a variable light chain domain. The variable heavy chain domain comprises an amino acid sequence exhibiting at least about 80% sequence homology with respect to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4. In some examples, the variable heavy chain region comprises an amino acid sequence exhibiting at least about 85%, 90%, or 95% sequence homology with respect to the amino acid sequence as mentioned above. The variable light chain domain comprises an amino acid sequence exhibiting at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-111 of SEQ ID NO. 1 and 1-110 of Petition 870260102302, dated 05 / 10 / 2026, page 30 / 103 22 / 46 SEQ ID NO. 3. In some examples, the variable region of the light chain comprises an amino acid sequence exhibiting at least about 85%, 90%, or 95% sequence homology with respect to the amino acid sequence mentioned above. Determination of binding activity for PD-L1, OX40-specific IgG derivatives by direct ELISA.
[0066] Purified antibody derivatives against PD-L1 or OX40 (anti-PD-L1 antibody derivatives or anti-OX40 antibody derivatives) were then applied for ELISA binding characterization to human PD-L1-Fc or OX40-Fc in a direct coated configuration. Figures 6 and 7 show the ELISA binding results for anti-PD-L1 and anti-OX40 antibodies, respectively. For PD-L1-specific antibodies, most derivatives showed similar or better binding activity than the reference antibody (Ref Ab, MPDL3280A, Roche).
[0067] Purified human PD-L1 or OX40 IgG1 Fc chimera (PD-L1-Fc or OX40-Fc, APBio) was dialyzed in phosphate-buffered saline (PBS), adjusted to 1 mg / mL, and then diluted with PBS to a final concentration of 1 μg / mL. Nunc-imuno Maxisorp 96-well plates were coated with 0.1 mL per well of recombinant PD-L1-Fc or OX40-Fc chimera, leaving wells empty for non-specific binding controls, and incubated at 4°C overnight. The PD-L1-Fc or OX40-Fc chimera solution was removed, and the plates were washed three times with 0.4 mL of wash buffer (0.1% Tween-20 in PBS). Blocking buffer, 0.4 mL Petition 870260102302, dated 05 / 10 / 2026, page 31 / 103 23 / 46 was added to all wells (5% low-fat milk powder in PBS) and incubated at room temperature for 1 hour with mixing. The blocking buffer was removed and the plates washed three times with 0.4 mL of washing buffer. Serial dilutions of the PD-L1 or OX40 test antibodies were prepared in PBS and 0.1 mL of diluted Ab was added per well. The plates were incubated for 1 hour at room temperature. The antibody solution was removed and the plates washed three times with 0.4 mL of washing buffer per well. Goat anti-human IgG labeled as horseradish peroxidase, F(ab')2 specific antibody (Jackson Immunoresearch # 109-036-097) was diluted 1:2000 with PBS and 0.1 mL was added per well. The plates were incubated for 1 hour at room temperature and washed with 0.4 mL of well-wash buffer. TMB reagent, 0.1 mL, (Invitrogen) was added and incubated for 1 to 5 minutes at room temperature.The reaction was stopped by the addition of 0.05 mL of 1 N HCl and the absorbance was read at 450 nm on a Bio-Tek Spectra. The EC50 calculated for the anti-PD-L1 antibody derivatives for PD-L1 showed that most derivatives have good binding activity, as well as MPDL3280A (Ref Ab) by direct ELISA (Figure 6). Conversely, most anti-OX40 antibody derivatives showed much lower binding activity when compared to the reference antibody (Ref Ab, GSK3174998) (Figure 7). Determination of binding activity for PD-L1 and OX40-specific IgG derivatives by FACS.
[0068] Purified antibody derivatives Petition 870260102302, dated 05 / 10 / 2026, page 32 / 103 24 / 46 (anti-PD-L1 antibody derivatives or anti-OX40 antibody derivatives) were also applied to flow cytometry to determine and compare binding activity with PD-L1 or OX40-expressing HEK293 cells. Figures 8 and 9 show the binding activity of the corresponding antibody derivatives, as indicated by FACS, with stable PD-L1 or OX40-expressing HEK293 cells.
[0069] FACS analysis of 293 PD-L1 stable expression cells stained with anti-PD-L1 antibody derivatives to examine PD-L1 binding activity: Stable expression cells were incubated with purified anti-PD-L1 antibody derivatives at 1 μg / mL, reference antibody (Ref Ab MPDL3280A), or with an isotype antibody as a negative control on ice for 1 hour. Cells were washed three times with 1x PBS and then incubated with Alexa-488 (H+L)-conjugated goat anti-human IgG (Invitrogen Inc.) on ice for another 1 hour. After staining, cells were washed three times with 1x PBS, resuspended in 1x PBS / 2% FBS before being analyzed by FACS Calibur (BD Biosciences, Inc.) and FlowJo (TreeStar, LLC). In the same scenario, the binding activity of anti-OX40 antibody derivatives to stable OX40 HEK293-expressed cells shown in Figure 9 was also performed using a similar strategy and analyzed as described above.As shown in Figure 8, most anti-PD-L1 antibody derivatives have good binding activity, as do reference antibodies. This indicates that the phage clones selected in the OmniMab library do indeed recognize native PD-L1 in cells.
[0070] This phenomenon is also observed for Petition 870260102302, dated 05 / 10 / 2026, page 33 / 103 25 / 46 as derivatives of anti-OX40 antibodies, as shown in Figure 9. FACS analysis of clone 2D5 of 293 stable OX40 expression cells stained with purified anti-OX40 antibodies leads to examining OX40 binding activity. Stable expression cells were incubated with 2 μg / mL of reference anti-OX40 Abs (OX40 reference) or reference anti-CD137 Abs (CD137 ref.) as a control antibody on ice for 1 hour. Cells were washed three times with 1x PBS and then incubated with Alexa-488 (H+L)-conjugated goat anti-human IgG (Invitrogen Inc.) on ice for a further 1 hour. After staining, the cells were washed three times with 1x PBS, resuspended in 1x PBS / 2% FBS before being analyzed by FACS Calibur (BD Biosciences, Inc.) and FlowJo (TreeStar, LLC). Binding to competition by ligands (ELISA assay)
[0071] The antibody derivatives were shown in the selectivity and binding affinity assay used to evaluate the anti-PD-L1 antibody derivatives of the present invention for their ability to block PD-L1 binding to PD-1.
[0072] Antibodies were tested for their ability to block the binding of the human PD-L1-Fc chimera (PD-L1-Fc) to recombinant human PD-1 / His (hPD1 / His) by ELISA. Purified recombinant hPD-1 / His (APBio) was dialyzed to 1 mg / mL in PBS and then conjugated with biotin (Abcam). The 96-well Nunc Maxisorp plate was coated with 250 ng of hPD-1 / His per well in PBS overnight. The hPD-1 / His solution was removed and the plates were washed three times with 0.4 mL of wash buffer (0.1% Tween-20 in PBS). Blocking buffer, 0.4 mL Petition 870260102302, dated 05 / 10 / 2026, page 34 / 103 26 / 46 (5% low-fat milk powder in PBS) was added to all wells and incubated at room temperature for 1 hour with mixing. During the blocking step, antibody stocks were diluted in the range of 200 nM to 0 nM in PBS with 2-fold serial dilution. The purified recombinant biotinylated PD-L1-Fc chimera was diluted to 4 μg / mL in PBS. PD1 / His-coated plates were washed three times with 0.2 mL of wash buffer (0.1% Tween 20 in PBS). 60 μL of antibody dilutions (anti-PD-L1 antibody derivatives or Ref Ab MPDL3280A) were added separately with 60 μL of biotinylated PD-L1-Fc chimera and incubated at room temperature for 1 hour. The plates were washed as described above. Streptavidin-HRP was diluted 1:2000 in PBS, 100 μL of the resulting solution were added to the wells of the washed bath and incubated at room temperature for 1 hour.The plates were washed as previously described, 100 μL of TMB substrate solution was added to each well and incubated for 10 minutes. The reaction was stopped with 50 μL of 1 N HCl and absorbance at 450 nm was read using the Bio-Tek reader and shown in Figure 10. It was demonstrated that partial antibody derivatives inhibit the PD-PD-L1 interaction by competitive ELISA. Most antibody derivatives revealed similar blocking activity when compared to the reference antibody (Ref Ab MPDL3280A). Enhanced stimulation of T cell activation by inhibiting the interaction of the PD-1:PD-L1 ligand with anti-PD-L1 antibody.
[0073] The PD-1 signaling pathway inhibits signals Petition 870260102302, dated 05 / 10 / 2026, page 35 / 103 27 / 46 moderate TCR / CD28 co-stimulation, with cytokine production being reduced initially without a decrease in T cell proliferation. As TCR / CD28 co-stimulatory signals weaken, the PD-1 pathway dominates, with a large reduction in cytokine production accompanied by a reduction in proliferation. Therefore, in order to confirm that PD-1 inhibition via inhibition of interaction with PD-L1, the human antibodies of the invention increase T cell activation, mixed lymphocyte reactions (MLRs) are performed.
[0074] Human whole blood monocytes were enriched with RosetteSep™ Human Monocyte Enrichment Cocktail (Cat. No. 15068) and cultured in differentiation medium, RPMI 1640 with 10% FBS, 100 ng / mL (1000 U / mL) GM-CSF, 100 ng / mL (500 U / mL) for 6 days. Differentiated dendritic cells (DCs) from monocytes were checked by DC-SIGN-PE, anti-CD14 conjugated with FITC Ab, anti-CD83 conjugated with PE Ab, or anti-CD80 conjugated with FITC Ab to validate differentiation and were found to be APCs in MLRs.
[0075] Allogeneic CD4+ T cells from human whole blood were isolated using the RosetteSep™ Human CD4+ T Enrichment Cocktail (Cat. NO. 15062). The purity of the CD4+ T cells was verified with anti-CD4-conjugated APC Ab to ensure purity above 95% and then labeled with 1 µM CFSE (CellTrace™ CFSE cell proliferation kit, Life Technologies, Cat. NO. C34554) for the T cell proliferation assay. Labeled CD4+ T cells were used for co-culture with immature DCs with different antibody derivatives, as Petition 870260102302, dated 05 / 10 / 2026, p. 36 / 103 28 / 46 indicated for 3 and 5 days, to verify if the antibody derivatives could restore T cell activation by blocking the interaction between PD-1 and PD-L1. After 3 and 5 days of incubation, the supernatant was collected for cytokine quantification, such as IL-2 and IFN-γ by ELISA. The addition of anti-PD-L1 antibody derivatives (clones 6, 32, 28, 51, 64, 27, and 37) to immature dendritic cell cultures plus allogeneic T cells resulted in an increase in T cell proliferation and cytokine production, compared to cultures treated with IgG isotype (iso #1, #2) and shown in Figures 11A and 11B. The production of IL-2 and IFN-γ increases significantly in MLRs compared to isotype antibody treatment after 3 days (Figure 11A) or antibody treatment after 5 days (Figure 11B), especially for the anti-PD-L1 antibody clone 6.The cytokine increase is still evident after 5 days of antibody treatment and similar to the reference antibody (ref), MPDL3280A. This indicated that clone 6 of the anti-PD-L1 antibody should be one of the potential derivations for the bispecific antibody compound. Anti-OX40 antibody agonist activity assay
[0076] In order to activate OX40 co-stimulation of T cell proliferation and cytokine production, purified antibody derivatives were functionally screened for their ability to enhance cytokine production, proliferation, and proliferation induction in human CD3+ T cells. The anti-CD3 antibody (OKT3, BioLegend Cat. No. 317304) and anti-OX40 antibody derivatives (clones B6, B70, B120, A4, B17, B19 and Petition 870260102302, dated 05 / 10 / 2026, page 37 / 103 29 / 46 B30), reference antibody (GSK3174998), or isotype antibodies (iso #1, #2) were coated onto the 96-well Maxisorp plate. Meanwhile, unchallenged human CD3+ T cells were isolated from human blood of healthy adult volunteers using a RosetteSep™ Human T Cell Enrichment Cocktail (STEMCELL Cat. NO. 15061) as described by the manufacturers. The isolated CD3+ T cells were then labeled by CFSE (CellTrace™ CFSE cell proliferation kit, Life Technologies, Cat. NO. C34554) and seeded as 1 x 10⁶ cells / mL into the antibody-precoated well containing RPMI 1640 medium, 10% fetal bovine serum, and 2.5 mM L-glutamine to determine cell proliferation and cytokine production. After 3 days of culture, the cells were collected for proliferation assay by flow cytometry and the medium was then analyzed for IL-2 and IFN-γ production by ELISA quantification.
[0077] The classification of anti-OX40 antibody derivatives with agonistic activity in T cell activation was shown in Figure 12A. All anti-OX40 antibody derivatives showed the ability to enhance CD3+ T cell activation in response to both dosage and reference antibody. Treatment with higher antibody doses showed noticeably higher T cell activation activity. Meanwhile, cytokine production (Figure 12B), such as IL-2 and IFN-γ, also revealed a similar T cell activation response, especially for the B17 clone of the anti-OX40 antibody. The cytokine is highly inducible after treatment with the anti-OX40 B17 antibody derivative for 3 days. The enhancement is very Petition 870260102302, dated 05 / 10 / 2026, page 38 / 103 30 / 46 greater than the reference antibody treatment; this implicated B17 clone should be one of the candidates for the construction of bispecific antibodies.
[0078] As shown in Figures 13A and 13B, both anti-OX40 antibody derivatives, clones B17 and B19, showed improved agonist activity in the assay after 3 days of treatment with anti-OX40 antibody derivatives (B17 or B19). IL-2 or IFN-γ production showed an obvious enhancement with antibody treatment and revealed action-dependent correlation. Higher cytokine production was recorded with higher antibody doses.
[0079] In order to evaluate the agonist activity of the OX40, B17 and B19 antibody derivatives, the EC50 was also determined, as well as the agonist activity assay and cytokine production were recorded for comparison. Construction, expression, and purification of the anti-PD-L1-OX40 scFv antibody.
[0080] As the bispecific antibody is designed as IgG based on a fused scFv format, the structure of the anti-immune checkpoint antibody is terminally fused at Fc with OX40 scFv. The antibody can be an inhibitory anti-immune checkpoint antibody, such as anti-PD-L1, anti-PD-1, anti-CTLA4, anti-LAG3, etc., or a stimulatory antibody, such as anti-CD28, anti-CD137, anti-CD27, anti-ICOS, etc. A linker is placed between the antibody Fc and OX40 scFv to generate the bispecific antibody, as shown in Figure 14.
[0081] In some modes, clone 6 of Petition 870260102302, dated 05 / 10 / 2026, page 39 / 103 31 / 46 anti-PD-L1 antibody is designated to be of the IgG form; on the other hand, the anti-OX40 antibody derivative would be transformed into the scFv format to fuse at the C-terminus of the Fc region in clone 6 of the PD-L1 antibody derivative. Transformation of the antibody to the scFv format may result in reduced binding activity or specificity; therefore, several anti-OX40 antibody derivatives were used for scFv transformation. Construction of the bifunctional anti-PD-L1 antibody Fc fused with OX40 scFv of full length (SEQ ID NO. 10 as clone A4, SEQ ID NO. 11 as clone B17, SEQ ID NO. 12 as clone B19 or SEQ ID NO. 13 as clone B120). A short flexible peptide linker (GGGGS)2 (SEQ ID NO. 14) was placed between, for example, the C-terminal of the anti-PD-L1 antibody heavy chain in the Fc region and the N-terminal module of OX40 scFv to ensure correct folding and minimize steric hindrance.The coding sequences for anti-PD-L1-OX40 scFv antibodies were shown in SEQ ID NO. 16 (clone B17 scFv heavy chain OX40 anti-PD-L1-clone 6) and NO. 17 (clone B19 scFv heavy chain OX40 anti-PD-L1-clone 6). The Fc fusion proteins of the constructed antibody were led by a signal peptide (SEQ ID NO. 15) and expressed by mammalian cells and purified from the supernatant of transfected cell cultures by one-step G protein chromatography. As shown in Figure 15, a purity greater than 90% can be obtained in a single-step purification process and shows that the purified fusion proteins have the correct molecular weight (Mw = 220kD). Enhanced stimulation of T-cell activation Petition 870260102302, dated 05 / 10 / 2026, page 40 / 103 32 / 46 for bispecific antiPD-L1-OX40 scFv antibody derivatives in MLRs
[0082] To determine the synergistic cooperation of the bispecific antibody in increasing T cell activation by inhibiting the interaction between PD-1 and PD-L1 and agonistic activation of OX40 signaling, the bispecific antibody derivatives anti-PD-L1-OX40 scFv were applied to MLRs as described above. IL-2 and IFN-γ production was then recorded after 3 or 5 days of antibody treatment. Mono-, combined, or bispecific antibodies were applied in equal or equal-mol amounts to compare the synergistic effect on enhancing T cell activation, and the IgG isotype was used as a negative control.As the data showed in Figures 16A and 16B, only the anti-PD-L1 antibody derivatives showed a significant induction of IL-2 after 3 days of treatment, as did the reference antibody, MPDL3280A. Conversely, the anti-OX40 antibody derivatives were unable to noticeably increase cytokine upregulation after 3 or 5 days of antibody treatment. This is represented by the reference antibody, GSK3174998. However, the combination of anti-OX40 and anti-PD-L1 antibodies showed a significant increase in cytokine production after 3 and 5 days of antibody treatment. The synergistic effect is also observed in the bispecific antibody treatment, and the increase in cytokine production is similar to that of the combination treatment. This indicated that the bispecific anti-PD-L1-OX40 scFv antibody derivatives also function well as a combination treatment. Petition 870260102302, dated 05 / 10 / 2026, page 41 / 103 33 / 46 antibodies without loss of any binding activity upon scFv transformation. Determination of aggregation and purity of bispecific antibody
[0083] Since purified anti-PD-L1-clone 6-OX40 clone B17 scFv Ab revealed a lower purity (74.07%) by SEC-HPLC analysis after single-column protein A chromatography purification, numerous antibody variants were generated to improve purity and reduce aggregation for the bispecific antibody in the present invention. The ligands described above were used to replace the ligand in OX40 B17 scFv in the bispecific antibody anti-PD-L1-OX40 Ab (SEQ ID NO. 16) and produced as anti-PD-L1-OX40 Ab-V1 to V4 (SEQ ID NO. 18 to SEQ ID NO. 21) in CHO cells. These variants were then purified and analyzed by XBridge Protein BEH SEC-HPLC column (Waters, Cat. No. 186007640). The data were summarized as shown in Table 1 below. One of the bispecific antibody variants, anti-PD-L1-OX40 Ab-V4, revealed a significant improvement in antibody purity. The purity increased from 74.07% to 92.27%.Therefore, the anti-PD-L1OX40 Ab-V4 antibody was used with additional genetic engineering to improve its purity. TABLE 1 Different ligands in OX40 B17 scFv Abbreviation Heavy chain / light chain Linker in OX40 817 scFv Reference Anti-PO-L1-0X40 Ab Anti-PO-L1-6-0X40 817 scFv-L1 HC / Anti-PO-L1 6 LC GGGGSGGGGSGGGGS (SEQ 10 NO: 39) Int. J. Mol. Sci. 2014, 15(12), 2365823671 Petition 870260102302, dated 05 / 10 / 2026, page 42 / 103 34 / 46 Anti-PO-L1-0X40 Ab-V1 Anti-PO-L1-6-0X40 B17 scFv-L2 HC / Anti-PO-L1 6 LC SSGGGGSGGGGGGSS RSSL (SEQ 10 NO: 40) None Anti-PO-L1-0X40 Ab-V2 Anti-PD-L1-6-0X40 B17 scFv-L3 HC / Anti- PD-L1 6 LC GGKGSGGKGTGGKGS GGKGS (SEQ 10 NO: 41) Virol J. 2008; 5:21 Anti-PD-L1-0X40 Ab- V3 Anti-PD-L1-6-0X40 B17 scFv-L4 HC / Anti-PO-L1 6 LC GSASAPTLFPLVS(SEQ ID NO. 42) DOI: 10.3892 / mmr. 2013.1502 Anti-PD-L1-0X40 Ab- V4 Anti-PD-L1-6-0X40 B17 scFv-L5 HC / Anti- PO-L1 6 LC GSTSGSGKPGSGEGSTKG (SEQ ID NO: 43) PMID: 8309948
[0084] To characterize the size distribution of bispecific antibodies, samples were loaded onto an XBridge Protein BEH SEC-HPLC column (Waters, Cat. No. 1860 07640) using a Waters Alliance 2695 Separation Module. The protein peak was detected at 280 nm using a Waters 2996 PDA detector. The mobile phase was 25 mM isocratic sodium phosphate (Sigma, Cat. No. 04272 and Cat. No. 04269) with 200 mM NaCl (AMRESCO, Cat. No. 0241), pH 6.8, at a flow rate of 0.4 mL / min. Peak percentages were determined by the parts of the peak area, as shown in Figures 17A to 17E.
[0085] The anti-PD-L1-OX40 Ab-V4 showed a significant improvement in purity (Figure 17E). The bispecific antibody was subsequently genetically engineered into the OX40 B17 scFv fragment to further improve purity. Several residues in the OX40 B17 scFv shown in Figure 18 were replaced with different amino acids, and the heavy chain variants were paired with the light chain of the anti-PD-L1 clone 6 to generate several bispecific antibody variants, from the anti-PD-L1-OX40-V5 to V12 antibody (SEQ ID NO. 22 to SEQ ID Petition 870260102302, dated 05 / 10 / 2026, page 43 / 103 35 / 46 NO. 29) and then expressed and purified as mentioned above. The purity of the bispecific antibody variants was summarized as follows in Table 2, anti-PD-L1-OX40 scFv-V5 revealed the best purity among these antibody variants. The purity is up to 96.46%. This shows superior purity for the manipulated bispecific antibody and also revealed good development potential for this bispecific antibody in the future. As shown in Figure 19, the integrity of anti-PD-L1OX40 Ab-V5 was also analyzed by SDS-PAGE and showed good integrity under both reducing and non-reducing conditions. TABLE 2 Antibody Purity Antibody Purity by SEC-HPLC (%) Anti-PD-L1-OX40 Ab-V4 92.27 Anti-PD-L1-OX40 Ab-V5 96.46 Anti-PD-L1-OX40 Ab-V6 86.36 Anti-PD-L1-OX40 Ab-V7 88.04 Anti-PD-L1-OX40 Ab-V8 90.00 Anti-PD-L1-OX40 Ab-V9 87.89 Anti-PD-L1-OX40 Ab-V10 86.56 Anti-PD-L1-OX40 Ab-V11 86.61 Anti-PD-L1-OX40 Ab-V12 84.78
[0086] Meanwhile, the manipulated bispecific antibody variants were also applied for evaluation of binding activity to PD-L1 and human OX40 by direct ELISA, as shown in Figure 20. All bispecific antibody variants, as indicated, Petition 870260102302, dated 05 / 10 / 2026, page 44 / 103 36 / 46 showed the same binding activity for human PD-L1 (Figure 21), this binding activity is similar to the anti-PD-L16 antibody. This phenomenon was also observed in the human OX40 binding assay (Figure 22). Only the anti-PD-L1-OX40 Ab-V10 showed weaker binding activity for human OX40 compared to other variants. This indicated that the genetic engineering of the OX40 scFv did not affect the OX40 binding activity. Binding activity is retained for PD-L1 or OX40. As the anti-PD-L1OX40 Ab-V5 revealed superior antibody purity and binding activity for PD-L1 and OX40, then the anti-PD-L1OX40 Ab-V5 was chosen for serum stability. Ex vivo serum stability
[0087] Stability was evaluated in human serum (BioreclamationlVT, Cat. No. HMSRM), as well as serum from relevant preclinical species: rhesus monkey (BioreclamationlVT, Cat. No. RHSSRM) and CD1 mouse (BioreclamationlVT, ref. No. MSESRM). Samples were added to serum from different species to a final concentration of 15 g / mL and incubated in a water bath at 37°C. Serum samples were collected after incubation times of 0, 1, 2, 3, 7, 10, and 14 days and stored frozen at -80°C until analysis. Quantification of sandwich ELISA
[0088] OX40-Fc was coated onto an ELISA plate (NUNC, Cat. No. 442404) with 100 μL at 1 μg / mL in PBS and incubated overnight at 4°C. The wash buffer was prepared as PBS with 0.1% Tween-20 (Sigma, Cat. No. P2287-500 mL) and the blocking buffer was prepared as 1% BSA (UniRegion, Cat. No. UR-BSA001-100G) in buffer. Petition 870260102302, dated 05 / 10 / 2026, page 45 / 103 37 / 46 wash. Serum samples were prepared with 10-fold dilution using 3x serial dilution in blocking buffer, and standards were prepared at 10 nM with 3x serial dilution in blocking buffer. Biotinylated PD-L1-Fc was labeled with the Biotin Fast Conjugation Kit (above, Cat. No. ab201796) using standard protocol and prepared at 30 nM in blocking buffer. Streptavidin-HRP (above, Cat. No. ab7403) was prepared at 1 μg / mL in blocking buffer. All samples were added to each well by 100 μL after the plates had been washed 3 times with washing buffer and incubated for 1 hour at room temperature. Development of TMB with a 100 μL solution of TMB (Invitrogen, Cat. No. 00-2023) for 2 minutes and stopped with 100 μL of 1N HCl solution (Merck, Cat. No. 1.00317.1000). Absorption OD 450 nm was read by an ELISA reader (Biotek, Powerwave XS).
[0089] The anti-PD-L1-OX40 Ab-V5 was chosen for ex vivo serum stability due to its superior purity and binding activity for PD-L1 and OX40. The purified bispecific antibodies were mixed with serum from different species, such as human, mouse, or monkey. After several days of culture, samples were collected and analyzed by sandwich ELISA to determine the amount of antibodies. As shown in Figure 23, the anti-PD-L1-OX40 Ab-V5 still showed good serum stability after 14 days of culture at 37°C. The antibody concentration is still above 70% in humans, mice, or monkeys. This indicates that the antibody also has good serum stability.
[0090] To measure anti-PD-L1 capacity Petition 870260102302, dated 05 / 10 / 2026, page 46 / 103 38 / 46 To modulate the responsiveness of T cells using OX40 Ab-V5, purified T cells were cultured with allogeneic dendritic cells, prepared by monocyte culture in GM-CSF and IL-4 for several days. Parallel plates were set up to allow collection of supernatants on days 3 and 5 to measure IL-2 and IFN-γ respectively using a commercial ELISA kit. As the data showed in Figures 24A and 24B, IL-2 and IFN-γ production is highly upregulated in the bispecific antibody treatment (V5), as well as in the combined treatment after 3 or 5 days of antibody treatment. Furthermore, the enhancement is clearly superior to treatment with anti-PD-L1 Ab or anti-OX40 Ab alone. This implied that the engineered bispecific antibody, V5, still possesses agonistic activity, as does the combined treatment, without loss of functionality and could be developed as a therapeutic antibody for various solid tumors or cancers in the future. Antitumor activity of a bispecific antibody (in vivo model)
[0091] The lack of rodent cross-reactivity of PD-L1 and OX40 to bispecific antibodies prevented the use of standard murine syngeneic tumor models or human xenograft tumor models for evaluating the anti-human tumor efficacy of the antibodies. Consequently, a novel huPBLSCID-Bg mouse tumor model was generated using a SCID-Bg mouse (CB.17 / lcr. CgPkrdcscidLystbg / Crl), harboring functional NK cells and mutation-free murine T and B lymphocytes (Bg). The anti-human tumor efficacy of the bispecific antibodies was evaluated using this model as described below. Petition 870260102302, dated 05 / 10 / 2026, page 47 / 103 39 / 46
[0092] Human prostate PC-3 was obtained from the American Type Culture Collection and cultured in RPMI1640 (Invitrogen) with L-glutamine, sodium pyruvate, penicillin / streptomycin, and 10% heat-inactivated fetal bovine serum (FBS, Gibco Cat. NO. 10437). Cells were grown to confluence in Falcon T-150 flasks. Subsequently, the cells were trypsinized (trypsin 0.25%-EDTA; Invitrogen) and growth was increased to a sufficient number of cells for inoculation. Peripheral blood lymphocytes (PBMCs) were isolated from heparinized blood using Lymphoprep™ according to the manufacturer's protocol (STEMCELL Technologies Inc.). The counted cell suspensions were combined so that each mouse received an injection of 0.75 x 10⁶ PBMCs and 3 x 10⁶ tumor cells in a single 0.1 mL bolus injection in PBS.In order to facilitate the growth of tumor cells cultured in mice, an additional 0.1 mL of Matrigel was then mixed with the combined cell suspension and immediately injected into the prepared mice.
[0093] For each mouse, a volume of 0.2 mL of the combined cell suspension was injected subcutaneously into the animal's right flank. After 14 days of inoculation, a solid tumor is formed, reaching approximately 250 to 300 mm3, and the bispecific antibody (3 mg / kg of Anti-PDL1-OX40 Ab-V5), PD-L1 reference antibody (Ref Ab, MPDL3280A), or control antibody (Isotype) is challenged twice weekly for three weeks with intraperitoneal (ip) injection. Tumor measurement was performed using a Pressier calibrator twice weekly, as well as the administration of test samples during the duration of the study. Petition 870260102302, dated 05 / 10 / 2026, page 48 / 103 40 / 46 experiments and body weights were also recorded. Tumor volume was calculated using the following formula: length x width² x 0.44 = volume (mm³) and plotted on a graph in Figure 25. Mice were removed from the study if the tumor volume reached 2000 mm³ or if the animal lost 20% of its body weight before the end of the experiment. Similar results were observed when tumors were measured on day 7 after inoculation, and animals were randomized according to tumor volume. For the animal study, each group contained 6 mice. As shown in Figure 25, the bispecific antibody showed significant antitumor efficiency in the PC-3 xenograft mouse model. Tumor size is checked 18 days after tumor inoculation, as well as with the reference antibody PD-L1, and continues to reduce below 100 mm³.The PC-3 xenografted mouse model has been preliminarily demonstrated to be a bispecific antibody antitumor drug and has revealed its potential to be a therapeutic drug in the future.
[0094] Collectively, these results indicated that the bispecific antibody sustains its immune checkpoint blockade at PD1 / PD-L1 signaling and agonistic activity for OX40 signaling. Studies are underway to further investigate the biological activity of these proteins using a suitable animal model, such as the PC-3 tumor in the humanized NOD.CgPrkdcscidll2rgtzwjl / SzJ (NSG) model.
[0095] The Fc region in the present invention may be of any isotypes, subclasses, allotypes or manipulated mutants of immunoglobulin, such as Fc fragments of Petition 870260102302, dated 05 / 10 / 2026, page 49 / 103 41 / 46 button and hole. EXAMPLES
[0096] The example below describes the generation of therapeutically suitable monoclonal antibodies targeting human PD-L1 and OX40. Compound human anti-PD-L1 and anti-OX40 antibodies were generated from anti-PD-L1 antibody clone 6 and anti-OX40 antibody clone B17, respectively. Human V-region sequence segments were obtained from unrelated human antibody sequence databases (germline and non-germline). Example 1. Generation of IgG antibodies that bind to PD-L1 and OX40
[0097] Certain antibodies provided by the present invention were originally generated from Fabs that bind to human PD-L1 or OX40. The Fabs were selected from a phage display library, the OmniMab phagemid library, after alternating cycling on the corresponding Fc fusion proteins (PD-L1Fc or OX40-Fc) and cells expressing the corresponding human protein (PD-L1 or OX40). After direct ELISA or cell-based ELISA, the positive clones were then sequenced for heavy chain and light chain. These Fabs include those designated as OM-PD-L1-6 and OMPDL1-32 etc. for PD-L1; OM-OX40-A4, OM-OX40-B17 and OM-OX40-B19 etc. for OX40. The PD-L1 antibodies PD-L1Clone 3, PD-L1-Clone 6, and PD-L1-Clone 32 disclosed in this application were generated from OM-PD-L1-6 and OM-PDL132. Meanwhile, the OX40 antibodies OX40-A4, OX40-B17, and OX40-B19 disclosed in this application were generated from... Petition 870260102302, dated 05 / 10 / 2026, pp. 50 / 103 42 / 46 OM-OX40-A4, OM-OX40-B17, and OM-OX40-B19 in HEK293 cells or CHO-S cells. The bispecific antibody targeting PD-L1 and OX40 simultaneously was designed as anti-PD-L1 6-OX40 scFv B17 and anti-PD-L1 6-OX40 scFv B19. The amino acid sequence of the variable region of the light chain and the variable region of the heavy chain of a given Fab are identical to the amino acid sequence of the variable region of the light chain and the variable region of the heavy chain, respectively. Example 2 - In vitro binding of anti-PD-L1-OX40 scFv to its corresponding target.
[0098] The bispecific anti-PD-L1OX40 antibody was constructed as shown in Figure 14 and expressed on HEK293 cells or CHO-S cells. The medium containing the bispecific antibody was purified by affinity chromatography of the culture supernatant using protein G chromatography. The purified antibody was then concentrated, followed by dialysis in PBS buffer and analyzed by SDS-PAGE, as shown in Figure 15. To test the direct binding of purified fusion proteins to PD-L1 or OX40 in ELISA, 100 ng / well of recombinant PD-L1 or OX40 was coated in a 96-well ELISA plate. Various concentrations of purified anti-PD-L1-OX40 scFv were then added to each well and incubated for 1 hour. After washing, a 1:5000 dilution of anti-Fab HRP conjugate (Jackson Immunochemicals) was added to each well and incubated for another hour. After the final wash, TMB substrate (Invitrogen Inc.) was added and the absorbance of OD at 450 nm was measured.The data analyzed by fitting the sigmoidal curve using GraphPad Prism 5 and EC50 are calculated. Petition 870260102302, dated 05 / 10 / 2026, pp. 51 / 103 43 / 46 Example 3 - Antigen binding specificity of anti-PD-L1-OX40 scFv by FACS analysis
[0099] To test the binding specificity of the anti-PD-L1-OX40 scFv antibody, stable PD-L1-expressing 293 cells, A549 or WiDr stimulated by IFN-γ, were stained with 1 μg / mL of anti-PD-L1-OX40 scFv antibody for 1 hour on ice before washing three times with 1x PBS. Bound antibody fusion proteins were detected with Alexa-488-conjugated goat anti-human IgG (H+L) followed by FACS analysis. The antibody isotype was used as a negative control for the test. The results showed that the anti-PD-L1-OX40 scFv maintains its antigen-binding specificity compared to anti-PD-L1 alone. The binding specificity of the anti-PD-L1-OX40 scFv antibody was also tested using stable OX40-expressing 293 cells. Example 4 - In vitro immunomodulatory effect of bifunctional proteins
[00100] To measure the ability of anti-PD-L1-OX40 scFv antibodies to modulate purified T cells, responsiveness to T cells will be assessed using allogeneic dendritic cells prepared by monocyte culture in GM-CSF and IL-4 for several days. Parallel plates were set up to allow collection of supernatants on days 3 and 5 to measure IL-2 and IFN-γ respectively using a commercial ELISA kit. The humanized anti-PD-L1 from Genentech / Roche, MPDL3280A, will be produced internally and used as a positive control. As shown in Figures 16A and 16B, IL-2 and IFN-γ production is highly increased in the bispecific antibody treatment, as well Petition 870260102302, dated 05 / 10 / 2026, pp. 52 / 103 44 / 46 as in the combined treatment after 3 or 5 days of antibody treatment. Specifically, the bispecific antibody composed of the anti-PD-L1 6 antibody clone and the anti-OX40 B17 antibody clone (anti-PD-L1-OX40 scFv B17 Ab) or combination (anti-PD-L1 6 Ab clone and anti-OX40 B17 Ab clone) showed that the increase in T cell activation is greater than the combination of the PD-L1 and OX40 reference (PD-L1 Ref Ab plus OX40 Ref Ab). This indicated that the anti-OX40 B17 antibody may possess a special epitope binding to result in better agonistic activity compared to the OX40 reference antibody, GSK3174998. Example 5 - Human leukocyte expansion induced by bispecific antibodies in vivo
[00101] The lack of detectable cross-reactivity of PD-L1 or OX40 antibodies with murine PD-L1 or OX40 and the requirement for the presence of human immune cells necessitated the development of models for the in vivo functional evaluation of bispecific antibodies. Mice with a genetic background carrying the mutation and severe combined immunodeficiency (SCID) deficiency in the common gamma chain of the IL-2 receptor (commonly referred to as NSG) are able to support the grafting of large numbers of human peripheral blood leukocytes (huPBL) and maintain the graft for at least 30 days (King et al., 2008). This mouse model, also known as the huPBL-NSG model, was used to evaluate the functional effect of systemic in vivo administration of antibodies on human immune cells.
[00102] Specifically, 6 million recently isolated human PBMCs were transferred Petition 870260102302, dated 05 / 10 / 2026, page 53 / 103 45 / 46 adopted by intravenous injection in huPBLNSG mice. Nine days after PBMC injections, the animals received a single dose of 1 mg / kg of monoantibody, antibody, bispecific antibody, or IgG4 isotype control antibody by intraperitoneal injection. On days 24 to 28 after PBMC grafting, PBMCs were stained with antibodies to human and murine CD45 and evaluated by flow cytometry. Forehead and side scatter profiles were used to determine lymphocyte gate. Bispecific antibodies were able to increase human leukocyte expansion, as evidenced by the increased proportion of human CD45+ cells in the peripheral blood of grafted mice. For each group, n was 6 mice. Example 6 - Inhibition of the growth of PC-3 or A498 tumor cells in huPBL-NSG by anti-PD-L1-OX40 scFv antibody
[00103] The PD-L1-positive human prostate cancer cell line, the PC-3 cell line (ATCC# CRL-1435), or the renal cancer cell line, A498 (ATCC(R)HTB-44™), can be used to establish xenograft models in huPBL-NSG mice. For tumor formation, 3 x 10⁶ PC-3 cells (or A498 cells) / mouse will be injected subcutaneously into huPBL-NSG mice, as described above. To evaluate the inhibitory effects on tumor growth, different concentrations of anti-PD-L1OX40 scFv antibody, reference antibody, or isotype antibody of 0.1–3 mg / kg will be administered intravenously twice weekly for 4 weeks in mice after 14 days of tumor cell implantation. The growth Petition 870260102302, dated 05 / 10 / 2026, pp. 54 / 103 46 / 46 of the tumor will be measured twice a week for up to 5 weeks, as described in the Fox Chase SCID® Beige mouse model. Example 7 - Pharmacokinetic evaluation of antiPD-L1-OX40 scFv in mice and monkeys
[00104] Bifunctional proteins, 10-40 mg / kg, anti-PD-L1-OX40 scFv will be administered to mice or monkeys by subcutaneous or intravenous injection. Serum samples will be collected at different times after injection for up to 15 days. Fc fusion protein concentrations in serum samples will be determined using a sandwich ELISA assay.
[00105] Although the present invention has been described in considerable detail with reference to certain embodiments thereof, other embodiments are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the embodiments contained in this document.
[00106] It will be evident to those skilled in the art that various modifications and variations can be made to the structure of the present invention without departing from the scope or spirit of the invention. In view of the foregoing, the present invention is intended to cover modifications and variations of this invention, provided they fall within the scope of the claims that follow. Petition 870260102302, dated 05 / 10 / 2026, p. 55 / 103
Claims
1 / 1 CLAIMS 1. An antibody or its antigen-binding portion that binds to PD-L1, characterized by comprising: a variable heavy chain domain comprising an amino acid sequence of at least about 80% sequence homology with respect to the amino acid sequence selected from the group consisting of SEQ ID NO. 2 and SEQ ID NO. 4; and a variable light chain domain comprising an amino acid sequence of at least about 80% homology with respect to the amino acid sequence selected from the group consisting of amino acids 1-111 of SEQ ID NO. 1 and 1-110 of SEQ ID NO.
3.
2. A pharmaceutical composition characterized by comprising the antibody or its antigen-binding moiety, as defined in claim 1, and at least one pharmaceutically acceptable carrier.
3. Use of the antibody or antigen-binding moiety, as defined in claim 6, characterized in that it is for the manufacture of a medicament for the treatment of cancer.
4. Use according to claim 3, characterized in that the cancer is selected from the group consisting of prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), and ovarian cancer. Petition 870260102302, dated 10 / 05 / 2026, pp. 56 / 103
